Peptide questions, answered

A short chain of amino acids joined by peptide bonds, conventionally up to around

50 residues, above which the same molecule is usually called a protein. Insulin is a

peptide. So is oxytocin, so is the glucagon-like peptide-1 your gut releases after a

meal, and so are several hundred synthetic analogues that exist only in laboratories.

"Peptide" describes a chemical architecture, nothing more. It is not a category of

effect, a safety class, or a claim. The category contains approved medicines with decades

of outcome data, hormones essential to life, cosmetic ingredients with modest surface

effects, and dozens of compounds that have never been given to a human under any

supervision. Grouping them by chemistry tells you as much about their effects as grouping

medicines by whether they are white powders.

Some sequences occur in the body. Almost nothing sold is in a natural state. The

molecules with useful duration of action have been deliberately engineered: a fatty

acid chain attached so they cling to albumin, residues substituted to resist enzymes,

ends capped, rings closed. These modifications are what make them work, and they are

precisely what makes them not natural.

Several widely sold "research peptides" have no natural counterpart at all.

No. Anabolic steroids are small lipid-soluble molecules that pass through cell membranes

and act on intracellular receptors; peptides are large, water-soluble, act mostly on

cell-surface receptors, and are destroyed by digestion.

They share a market and a set of forums, not a pharmacology. The comparison is worth

resisting in both directions: peptides are not "safer steroids", and they are not

harmless because they are different from steroids.

It depends entirely on which peptide and what is being done with it. Approved peptide

medicines (insulins, GLP-1 receptor agonists, and others) are prescription-only

medicines, lawful to possess with a prescription and unlawful to supply without one.

Unapproved peptides sit in a murkier position. Selling or supplying an unlicensed

product for human use is a medicines offence in the UK, which is exactly why vendors

label everything for laboratory use. Personal possession is generally not itself

criminalised for most of these compounds, but importation may be intercepted, and any

substance also controlled under other legislation carries its own separate position.

This is a genuinely unsettled area. If your question is a legal one, ask a lawyer, not

a peptide site.

Broadly similar in shape. Approved products are prescription medicines. Unapproved

substances may not lawfully be marketed for human use, so they are sold labelled for

research, which is the same shield used in the UK.

The FDA has separately assessed a number of peptides frequently sold to consumers and

placed them in a category it considers unsuitable for pharmacy compounding, citing

insufficient safety characterisation. That is a public, searchable position and worth

finding for any specific compound you are reading about.

It is a real label with a real original purpose. Genuine laboratory reagents are not

manufactured to the standards required for human use, and the designation exists to say

so.

Used by a vendor selling single-dose vials with reconstitution guides to individuals

who are obviously not laboratories, it functions as something else: a liability shield

that allows an unapproved compound to be sold to consumers while formally disclaiming

the human use everyone in the transaction expects.

It is worth being clear about what the label does not promise. It does not promise

sterility. It does not promise pharmaceutical-grade manufacture. It does not promise

that the vial contains what the label says, in the quantity stated. It carries no

regulatory obligation on any of those points, because the material is not regulated as

a medicine. The phrase is a statement about who is liable, not about what is in the vial.

The related term "research peptide" is a commercial category, not a scientific one. It

describes a compound sold in vials that has not been approved as a medicine anywhere,

usually because nobody has completed, and in most cases nobody has started, the human

trials approval requires. The category is defined by an absence of evidence, not by any

shared property of the molecules in it.

Everything that has been checked.

An approved medicine has a dossier a regulator has examined: how it is manufactured and

whether that process is reproducible; what happens to it in the body; what it does in

humans, measured against a comparator, in a trial designed before the data existed; what

harms appeared and at what rate; who should not receive it. After approval it is

monitored, and rare harms surface through pharmacovigilance systems.

A research chemical has none of this. Not a weaker version: none. The identity in the

vial is unverified, the dose-response in humans is unknown, the harms are undescribed,

and there is no mechanism by which anyone would find out if it were harming people.

They can prescribe approved peptide medicines, including off-label, a legitimate,

common practice where a clinician judges the evidence supports use outside the licensed

indication and takes responsibility for that decision.

They cannot prescribe a compound with no marketing authorisation as though it were a

medicine, and a clinic offering an unapproved peptide is not doing the same thing as

off-label prescribing, however similar the framing sounds. That conflation is a

recurring feature of clinics selling these compounds.

Somewhat better regulated than grey-market vials, and considerably less regulated than

approved medicines. Compounded preparations are not assessed for safety or efficacy

before they are supplied, and quality has varied widely in practice.

Regulators in both the UK and US have issued repeated public alerts about compounded and

falsified injectable peptide products, including some presented as licensed devices. That

these alerts keep being necessary is the relevant data point.

Many are. The WADA Prohibited List includes growth hormone secretagogues,

growth-hormone-releasing peptides, several growth factors and various other peptide

classes, a number of them prohibited at all times rather than in competition only.

The list is published free and updated annually. Anyone tested under an anti-doping code

should read the current version rather than trust a vendor's characterisation of it.

"Undetectable" is a claim that has aged poorly for essentially every substance it has

been made about.

Yes, several are among the best-evidenced medicines in current use. Insulin analogues.

GLP-1 receptor agonists such as semaglutide and liraglutide, and the dual GIP/GLP-1

agonist tirzepatide, tested across the SUSTAIN, STEP, SURPASS and SURMOUNT trial

programmes, with the SELECT cardiovascular outcomes trial reporting a reduction in major

adverse cardiovascular events in people with overweight or obesity and established

cardiovascular disease. Octreotide. Teriparatide. Various GnRH analogues.

This list is the argument, not a counterargument. What these compounds have in common is

years of engineering, large randomised trials with pre-specified endpoints, and known

adverse effect profiles, which is exactly what the peptides sold online do not have.

For most compounds marketed to consumers there is essentially nothing. The typical

evidence base is a mechanism proposed in cell culture, one or two rodent studies often

from a single research group, and no human efficacy trial of any size. That is not a

slightly weaker version of a drug approval package. It is the first fortnight of a

process that normally takes a decade and usually fails.

It has a substantial rodent literature, much of it from one research group, describing

effects on tendon, gut and other tissues. That literature is real and it is why the

compound is interesting.

What it does not have is human efficacy evidence. As far as the peer-reviewed literature

goes, no randomised controlled trial in humans has reported efficacy for any indication.

A small number of trials have been registered over the years; results have not appeared in

the peer-reviewed literature in a form that would support the claims made for it. Its

pharmacokinetics in humans are not well characterised, and its long-term safety profile in

humans is not characterised at all.

"Hundreds of studies" is doing a lot of work in that sentence. Volume of publication is

not weight of evidence, particularly when the publications are concentrated in one group

and one species.

Several forces push the same way and nothing pushes back.

A mechanism is easy to describe and hard to check: "upregulates growth factor receptor

expression" sounds like a finding and is usually an in vitro observation. Positive results

get published and null results do not, so the visible literature is already skewed. The

people writing the summaries frequently sell the compound. Nobody with a financial stake

funds the trial that could disprove the claim, and no regulator requires one, because the

product is not sold as a medicine.

And on the demand side, the strongest confounders in all of clinical research (the

placebo effect, natural recovery, regression to the mean, and expectation) all operate at

full strength in exactly the setting where these compounds are used: unblinded, uncontrolled,

self-assessed, and on subjective outcomes like pain, energy and recovery. Injections produce

larger placebo responses than tablets. Subjective endpoints produce larger ones than

objective measures. Both apply here.

Because it cannot distinguish the compound from everything else that was happening.

Most injuries improve. Most symptoms fluctuate around a mean, and people start

interventions at the bad end of that fluctuation, so improvement is the statistically

expected outcome regardless of what was taken. Anyone who has spent money and effort on

something is motivated to notice benefit. And nobody posts about the eight weeks where

nothing happened.

None of this means an individual experience is dishonest or imagined. It means the design

of the observation cannot separate the effect from the noise, which is precisely the

problem controlled trials were invented to solve.

Five questions, in order.

Species. Human, or mouse? Most peptide citations are rodent, and the translation

failure rate from promising animal results to human benefit is very high across all of

drug development.

Design. Randomised, controlled, blinded? Or open-label, uncontrolled, or a case

series? For any subjective outcome, unblinded results are close to uninterpretable.

Size. How many participants? A positive result in twelve people is a hypothesis. Small

studies that reach statistical significance systematically overstate the effect size.

Endpoint. Was the reported outcome the one the study was designed to measure, or one

found afterwards? Check whether it was pre-registered.

Interests. Who funded it, who ran it, and does anyone involved sell the compound?

Then read the abstract's own limitations section. Authors are usually more candid about

their study's weaknesses than the people citing it.

A preprint is a real manuscript that has not yet been checked by anyone independent. Some

are excellent and go on to publication unchanged; some contain errors that peer review

would have caught, and some are never published at all.

The problem is not preprints. It is citing one as though it were a peer-reviewed finding,

which is common in peptide marketing. If a claim rests on a preprint, check whether it has

been published since, and if it has been sitting unpublished for two years, ask why.

A randomised, controlled, blinded trial in humans, pre-registered with a primary endpoint

declared in advance, adequately sized, reporting a clinically meaningful effect on an

outcome people care about, and then replicated by an independent group.

That is the standard, and it is not an unreasonable one. It is what every medicine in your

cabinet had to clear. Any compound for which it has never been attempted is not

"promising but under-researched". It is untested, and the two phrases describe very

different situations.

Because the peptide bond is what digestive enzymes exist to cut. Swallow a peptide and

proteases in the stomach and small intestine dismantle it, and whatever survives faces an

intestinal wall that large water-soluble molecules cross very poorly. Oral bioavailability

for unmodified peptides is typically well under 1%, and frequently indistinguishable from

zero.

Injection bypasses both problems. It is not a preference or a cultural habit. It is a

consequence of the chemistry.

A few do, and the exceptions are instructive. Making a peptide orally viable requires

serious engineering (cyclisation, unnatural residues, absorption enhancers formulated

into the tablet), and the result is a specific, patented, extensively tested product, not a

molecule that happens to survive.

An oral version of a peptide normally given by injection, sold without any of that

engineering, will not have solved a problem the pharmaceutical industry spends hundreds of

millions on. The default assumption for an unlicensed oral peptide product is that it is

destroyed before absorption.

Nasal and sublingual routes at least avoid the gut, and both are legitimate for some

molecules. Desmopressin and several GnRH analogues are given nasally. But absorption

across those membranes is still poor for most peptides, highly variable between

individuals and between doses, and critically dependent on the formulation rather than

the molecule. "It's the same peptide, just sublingual" ignores the part that actually

determines whether any of it arrives.

Some, modestly, and the honest version is less exciting than the advertising.

Certain short peptides do have measurable effects on skin in controlled studies:

copper tripeptide and various signal peptides have reasonable in vitro and some clinical

data for collagen-related markers. But the outermost skin layer is an effective barrier

to molecules of this size, concentrations in finished cosmetic products are often low and

undisclosed, and the endpoints measured are frequently instrumental rather than visible.

The general position: real but small, better evidenced than injectable research compounds,

and consistently oversold.

Dissolving a freeze-dried solid back into liquid. Peptides are supplied lyophilised

because a dry solid is far more chemically stable than a solution, so the liquid form is

created only when it is about to be used.

We describe what the term means because you will meet it constantly in this material. We

do not publish reconstitution procedures, diluent guidance or volume calculations, because

those are preparation instructions for injecting unapproved substances, and that is not

what this site is for.

A properly constituted COA reports the analytical results for one specific manufactured

batch. To be worth anything it needs, at minimum:

• a batch or lot number that matches the vial in front of you : this is the whole basis

of the document, and generic undated certificates are extremely common;

• a test date and the name of the testing laboratory, ideally one independent of

the seller;

• an HPLC chromatogram, not merely a purity percentage: the trace shows what else was

in the sample and whether the method could resolve it;

• a mass spectrum confirming molecular weight, because purity says nothing about

identity;

• the salt form and net peptide content;
• and for an injectable, sterility and endotoxin results.

A number typed into a template is not a certificate. Neither is a chromatogram with the

axes cropped, or a COA whose batch number does not match what you were sent.

There is also a limit to what any seller-supplied certificate can establish. Testing

commissioned by the seller carries an obvious conflict of interest, and the deeper problem

is chain of custody: you cannot verify that the material tested is the material shipped.

Independent analyses of consumer-market peptides have repeatedly found discrepancies

between label and contents: wrong quantity, wrong compound, degradation products,

contamination. Without testing the specific vial you hold, its contents are an assumption.

Purity answers one narrow question: what proportion of the peak area in that chromatogram

belonged to the target compound.

It does not tell you the vial contains the compound at all. That requires mass

spectrometry. It does not tell you how much is present. That requires a potency assay

against a reference standard. It does not tell you whether the 1% is inert or biologically

active. It does not tell you whether the material is sterile or endotoxin-free. And it

cannot detect epimers, because a residue that has flipped from L to D has exactly the same

mass and may not separate on a standard method.

A vial can be 99% pure and still be the wrong molecule, in the wrong quantity, contaminated

with pyrogens.

Because the label usually states total mass, and a lyophilised peptide is not pure peptide.

It includes residual water, bulking agents, and the counter-ion from purification, most

commonly trifluoroacetate, which alone can account for a substantial share of the mass.

Net peptide content for a TFA salt is typically somewhere around 70-85%. That figure is

routinely absent from unlicensed product labelling, so the stated quantity can overstate

the actual amount of compound by a fifth or more.

Purity is chromatographic: what fraction of what was detected is the target. Potency is

quantitative and functional: how much active compound is actually there, measured against

a reference standard or by biological assay.

They diverge constantly. A vial can be highly pure and substantially under-filled, or

contain material that is chemically correct but partially degraded and functionally weaker.

Almost every certificate you will see online reports purity. Very few report potency, and

potency is the one that determines what is actually in the vial.

Because endotoxin is not alive and sterilisation does not remove it. It is a fragment of

the outer membrane of Gram-negative bacteria: heat-stable, filter-passing, and a potent

trigger of fever, chills and inflammatory response when injected.

A preparation can pass sterility testing, contain no viable organisms whatsoever, and still

cause a severe febrile reaction. This is one of the concrete mechanisms by which

manufacturing quality translates into physical harm rather than just reduced effect.

Water is the main culprit, which is why peptides ship freeze-dried. In solution they

undergo hydrolysis, oxidation of susceptible residues, deamidation of asparagine and

glutamine, and aggregation; removing the water slows all of it by orders of magnitude.

It is also why the visible contents of a vial are mostly bulking agent. There is often

very little actual peptide there, and it needs something to form a cake around.

Beyond water: heat, oxygen, light, extremes of pH, mechanical agitation, and repeated

freeze-thaw cycles. Different sequences are vulnerable to different things: methionine and

cysteine oxidise, asparagine and glutamine deamidate, and sequences prone to aggregation are

destabilised by shaking and by concentration.

Which is to say stability is sequence-specific. General claims about how long "peptides"

last are not meaningful without knowing which one.

For an approved medicine, the manufacturer has run formal stability studies and the expiry

date reflects them. For unlicensed material, there is no such data. Any shelf life quoted is

an estimate at best, and the storage history before it reached you is entirely unknown.

Cold-chain handling during shipping is a particular blind spot: a product may have spent days

at ambient temperature in transit, and nothing on the vial records it.

Not reliably. Visible cloudiness, particulates, discolouration or a collapsed cake all

indicate a problem, but the absence of those signs indicates very little. Significant

chemical degradation and early aggregation are invisible, and by the time a solution looks

wrong, far more has gone wrong than you can see.

Appearance is a test that can fail but cannot pass.

No. Sterile water contains no preservative. Bacteriostatic water contains a small amount of

benzyl alcohol, which inhibits microbial growth and allows a vial to be entered more than

once.

We define the terms because they appear constantly in this material. We do not publish

guidance on selecting diluents or preparing solutions, for the same reason we do not publish

dosing: it is instruction for administering unapproved substances.

They fall into three groups, and it is worth keeping them separate.

Product harms : the vial contains the wrong compound, the wrong quantity, degradation

products, endotoxin, or microbial contamination. These are documented in regulatory alerts

and independent testing, and they are the failure mode that has nothing to do with the

intended molecule.

Procedural harms : injection-site infection, abscess, and injury from non-sterile

technique. These are well characterised in any population injecting outside clinical care.

Pharmacological harms : the actual effects of the compound. For most research peptides

these are simply unknown in humans, and that is the point. Several classes carry specific

theoretical concerns worth naming honestly: compounds acting on growth pathways in anyone

with an undetected malignancy; melanocortin agonists and pigmented lesions; anything

affecting glucose regulation, blood pressure or hormonal feedback in people with undiagnosed

conditions.

Unknown is not the same as safe. It is the absence of the information that would let anyone

say either way.

Direct questions, and the answers are informative whichever way they go.

• Is this an approved medicine, and if so, for what indication? If you are prescribing it

off-label, what evidence supports that?

• If it is not approved anywhere, what is the legal basis on which you are supplying it?
• What human trial data exists (randomised, controlled, in people like me)?
• What are the known adverse effects, and what is the monitoring plan?
• Do you or the clinic have a financial interest in the product, beyond the consultation fee?
• What would make you stop, and what would make you say this isn't working?

A clinician who answers these plainly is worth listening to. One who deflects to

testimonials, mechanism-speak, or "the studies are out there" has answered the question.

Everything, specifically, and without editing it for embarrassment. What the substance was

by its chemical or research name, where it came from, how long it was used, and what changed.

Clinicians in emergency and general practice see this more often than people expect, and

the failure mode that actually causes harm is a patient who omits it and gets investigated

for the wrong thing. Diagnostic time lost is a much bigger practical risk than judgement.

In the UK, through the MHRA Yellow Card scheme, which accepts reports directly from members

of the public as well as from healthcare professionals. In the US, through the FDA's MedWatch

programme.

Both accept reports about unapproved products. This matters more than it sounds: substances

used outside the licensed system generate no safety signal at all, so their harms accumulate

without anyone being able to see the pattern. A report is the only mechanism by which that

changes.

Not as a category, and the question itself imports the wrong frame. Safety is a property of

a specific product, at a specific exposure, in a specific person, for a specific purpose,

which is why approval is granted to a product for an indication rather than to a molecule.

Insulin is essential to millions of people and kills people every year through error. The

useful question is never "is this safe" but "what is known about the risks, and by whom, and

how would anyone find out if it were harming me".

For most compounds discussed on this site, the answer to that last part is: nobody would.

No. Not a compound, not a supplier, not a clinic, not a protocol. We have no commercial

relationship with anyone in this market and we do not accept vendor advertising or

sponsorship.

The purpose here is to make the evidence (and much more often the absence of it)

legible enough that you can evaluate a claim without having to trust us either.

All of these are free and none of them are selling anything.

PubMed (pubmed.ncbi.nlm.nih.gov): the primary biomedical literature. Search the

chemical name and add AND randomized (American spelling, because that is how the

database indexes it) to see whether human trials exist at all.

ClinicalTrials.gov and the ISRCTN registry : registered trials, including ones that

were abandoned or never reported. The gap between registered and published is often the

most informative thing about a compound.

MHRA and FDA : safety alerts, enforcement actions, and the FDA's published

assessments of substances proposed for compounding.

EMA assessment reports : unusually detailed public evaluations of approved medicines,

including the negative findings and unresolved concerns that do not appear in company

materials.

Cochrane Library : systematic reviews, when one exists.

WADA Prohibited List : updated annually, free, definitive for anyone tested in sport.

Ask what species, and ask whether there was a control group. Those two questions eliminate

the great majority of claims made about peptides online, and they require no specialist

knowledge to apply.

The second habit is to search the databases directly rather than through a general search

engine, using the chemical or research name rather than a marketed one. Vendor sites are

optimised aggressively for peptide names and will otherwise dominate the results. If

PubMed returns fewer than a dozen papers for a compound, most of them rodent studies, and

no registered human trials, you have already learned the most important thing about it,

and you learned it in about ninety seconds.

# The questions everyone is asking

The most searched and most discussed peptide questions, from search data and the

communities where people compare notes, answered the same way as everything else

here: honestly, and graded against the evidence.

Honest ranking, by strength of evidence:

Semaglutide and tirzepatide sit at the top. Both are licensed medicines in the UK and US, tested in randomised trials of thousands of people. On average, trial participants lost around 15% of their body weight on semaglutide and around 20% on tirzepatide's higher doses. In the two head-to-head trials run so far, tirzepatide produced more weight loss. Semaglutide has the broader proof that the weight loss actually improves health: large trials showed fewer heart attacks and strokes, plus benefits for kidneys and liver.

Retatrutide produced the biggest numbers yet seen, around 24% in its phase 2 trial, but it is not approved anywhere. Its phase 3 results exist so far only as company press releases, with no published safety data.

Cagrilintide on its own was middling in its one phase 2 trial. Its real role is combined with semaglutide, where the pair produced around 20% weight loss. That combination is under regulatory review, not yet approved.

So "best" depends what you mean. Best proven: the licensed pair. Biggest headline figures: the investigational ones, with far less known about safety. And anything sold online under any of these names is unregulated material, not the tested medicine. If weight loss is the goal, the strongest starting point is a conversation with a prescriber who knows your history.

The receptor count is the easiest way to hold them in your head. Semaglutide switches on one receptor, GLP-1, a gut hormone signal that dampens appetite. Tirzepatide switches on two, adding GIP, another gut hormone. Retatrutide switches on three, adding the glucagon receptor, which is thought to raise the energy your body burns as well as cutting what you eat.

More receptors has, so far, meant more weight loss. Published trial averages: roughly 15% of body weight for semaglutide, up to about 21% for tirzepatide, and about 24% for retatrutide in its phase 2 trial. Tirzepatide has also beaten semaglutide directly in two head-to-head trials. Nobody has run a head-to-head against retatrutide, so its bigger number is a comparison across different trials, which is weaker evidence.

But "better" has another axis: proof. Semaglutide and tirzepatide are licensed medicines with huge safety datasets. Semaglutide has the broadest evidence that the weight loss improves actual health, covering heart, kidneys and liver. Retatrutide is approved nowhere, its phase 3 results are so far press releases only, and it raised heart rate in trials, a question only a long outcome trial can settle.

So: most weight loss proven head-to-head, tirzepatide. Most proven health benefit, semaglutide. Biggest unverified numbers, retatrutide. Which of those matters most for you is exactly the question for a prescriber who knows your history.

Cagrilintide is a lab-made, long-lasting version of amylin, a hormone your pancreas releases alongside insulin when you eat. Amylin's job is telling your brain the meal is done. So while drugs like semaglutide mainly dial down hunger between meals, cagrilintide makes meals end sooner. Different lever, same direction.

On its own it has one published trial, a phase 2 study, where the weight loss was respectable but not remarkable, roughly in line with older licensed daily injections. The developer didn't take it further alone.

Its real role is the combination with semaglutide, usually called CagriSema. The logic: two separate fullness pathways working in parallel. In the big phase 3 trial the combination produced around 20% average weight loss over about 16 months. That's a strong result, though honestly a bit short of what many expected, and not clearly better than tirzepatide (a comparison across separate trials, so hold it loosely). The extra benefit from the cagrilintide half looks more modest than the headline figure suggests.

Where it stands: not approved anywhere, alone or combined, though the combination has been submitted to regulators. Against retatrutide there is no head-to-head trial at all, so nobody can honestly say which comes out ahead. And anything sold online as cagrilintide is unregulated material of unverified content, not the trial product.

There isn't one, and anyone who names a winner is guessing.

The two most talked about are BPC-157 and TB-500. Both have a real, sizeable body of animal research showing faster healing of tendon, muscle and ligament. Neither has a published trial showing it does that in a person.

For BPC-157 the numbers are stark: a 2025 systematic review screened 544 papers and found 35 animal studies and one clinical item, a look back at 12 people given a knee injection, 7 of whom reported relief. A proper randomised trial in hamstring strain is registered and recruiting, and until it reports, nobody knows. Nobody has even identified what BPC-157 binds to in the body.

TB-500 is the odd one. The natural peptide it comes from, thymosin beta-4, genuinely reached large late-stage human trials, but for dry eye disease, and those trials did not produce a published win on their main measures. What vendors sell as TB-500 is usually a short seven amino acid fragment, not the molecule those trials used, so the results don't read across.

So the honest summary: interesting biology, no human proof, unregulated manufacture, and both banned in sport at all times.

If you have an injury that isn't settling, the thing with actual evidence behind it is getting it properly diagnosed. A physio or doctor who can see the joint beats any vial.

They are completely different molecules, and neither is proven in people, so "better" doesn't really have an answer yet.

BPC-157 is a chain of 15 amino acids, said to come from a protein in stomach fluid, although that parent protein has never been independently isolated. After thirty years of research nobody knows what it binds to. Its effects in animals are described through downstream changes, mainly new blood vessel growth and effects on fibroblasts, the cells that lay down repair tissue.

TB-500 is sold as a stand in for thymosin beta-4, a natural 43 amino acid peptide that holds a reservoir of actin inside your cells and so controls how fast a cell can move into a wound. What is usually in the vial is a seven amino acid piece of it. That fragment carries some, but not all, of the parent peptide's activity, which matters because every human trial used the full length version.

The two are often bought together as the "Wolverine stack", on the theory that one works locally and one works body wide. That theory has now been tested: a 2026 rat study compared each alone against both together on Achilles tendon healing and found the pair no better than either one on its own. There are no human trials of the combination at all.

Both are banned in sport at all times.

Partly, and much less than the marketing says.

GHK is a genuine human molecule, a three amino acid peptide found in your own plasma, and it grips copper tightly. Copper matters because it is the cofactor for lysyl oxidase, the enzyme that cross links collagen and elastin. That is a proper biological rationale, better than most cosmetic ingredients can claim.

Then the evidence gets awkward. The best controlled skin trial, in people recovering from laser resurfacing, used blinded assessors and computer analysis of the photographs. It found no difference between the copper peptide regimen and the control on redness, wrinkles or skin quality. The only measure that favoured it was what patients said about their own skin. The famous study everyone cites, 71 women and a facial cream, is a conference abstract that cannot be found in any indexed database, so its methods can't be checked.

The strong human data for GHK-Cu is real but it is about diabetic foot ulcers healing faster with a gel, thirty years ago, never replicated.

For hair there is essentially nothing.

Injected is a different question again. Every controlled human study used it on the skin. Injecting sends a copper complex into your bloodstream, bypassing the gut controls that normally limit how much copper you absorb, and copper overload damages liver and brain. Nobody has published pharmacokinetics or safety data for that route.

It's two compounds aimed at the same system from two angles.

Your growth hormone system works like this: the hypothalamus in your brain releases GHRH, which tells the pituitary gland to let out a burst of growth hormone; your liver responds by making IGF-1. The bursts matter, it is a pulsed system, not a tap.

CJC-1295 is a copy of GHRH, redesigned to survive in the blood. The version with DAC clips onto albumin, a blood protein, giving it a half life of roughly a week instead of minutes. Ipamorelin works through a different door, the ghrelin receptor, and its selling point is real: unlike older peptides in its family it releases growth hormone without also pushing up cortisol and prolactin.

Now the evidence. CJC-1295 has exactly two published human studies, both from 2006, both measuring only hormone levels in healthy volunteers. Its development was abandoned that year after a phase 2 trial was halted. Ipamorelin has one proper randomised trial, in recovery of gut function after bowel surgery, and it failed, so development stopped. Between them, not one study has ever measured muscle, fat, sleep or recovery in a person.

The combination has never been studied at all. Worth knowing too: most vendors sell the "no DAC" version of CJC-1295, a different molecule with no published trial of its own.

Both are banned in sport at all times.

KPV is about as small as a peptide gets: three amino acids, lysine, proline and valine. It is the tail end of alpha-MSH, a natural hormone, specifically its last three positions. Chopping the hormone down to that tail keeps most of the anti inflammatory activity while losing the parts that affect skin pigment and appetite, which is the point of using the fragment.

The mechanism is genuinely neat. KPV is carried into the cells lining your gut by PepT1, a transporter built for small peptides. Once inside it damps down NF-kappaB, a master switch for inflammatory signalling. PepT1 is barely present in a healthy colon but ramps up in an inflamed one, so the peptide is drawn in mostly where there is trouble. Separate labs have reproduced benefit in two different mouse models of colitis.

Where it stands: no human being has been given KPV in any published or registered trial. Not one. The mechanism was established in 2008 and the human record is still empty, despite heavy marketing for gut problems, skin conditions and mast cell disorders.

One telling detail. Almost all research since has gone into elaborate delivery systems, nanoparticles and hydrogels, to get KPV where it needs to go. That is a strong hint the plain peptide does not survive administration well.

You will also see it inside the KLOW blend, with GHK-Cu, BPC-157 and TB-500. That four way combination has never been tested in anything.

They are forum nicknames, not categories with any science behind them.

Wolverine is BPC-157 plus TB-500, named after the comic character who heals fast. The idea is that one works at the injury site while the other works body wide. That division of labour is a community story. A 2026 rat study tested each one alone and both together on tendon healing, and the pair did no better than either alone.

GLOW is the Wolverine pair plus GHK-Cu, a copper carrying peptide, which shifts the aim from injury to skin, hair and looks. Nothing has tested those three together, in people or in animals, and every controlled human trial of GHK-Cu used it as a cream on the skin rather than an injection.

KLOW adds KPV, a small anti-inflammatory fragment of a natural hormone, to GLOW. Nothing has tested those four together either, and KPV has no human trials at all.

One practical point about the pre-blended vials these are often sold as. A certificate of analysis on a blend is much harder to read than one on a single peptide, because the lab has to separate several molecules at once and you lose the ability to check each one against its own reference. You also cannot drop or adjust one component, and if you react badly, you cannot tell which of them caused it.

They are two quite different things, despite both being sold as mitochondrial peptides.

SS-31, properly called elamipretide, is a four amino acid peptide that concentrates in the inner membrane of the mitochondrion and binds cardiolipin, the fat that keeps that membrane's machinery organised. It is the only compound in this class with approved labelling: the US regulator granted it accelerated approval in September 2025 for muscle strength in Barth syndrome, a rare genetic condition of cardiolipin handling. Read the rest of its record honestly, though. Its large randomised trials in mitochondrial myopathy, heart failure and macular degeneration all missed their main endpoints, and even the Barth approval rests on an open label extension where everyone knew they were being treated.

MOTS-c is a 16 amino acid peptide encoded inside mitochondrial DNA itself, which is genuinely striking biology. In mice it switches on AMPK, a cellular energy sensor, and improves insulin sensitivity. In humans, no completed trial of giving it to people has ever been published. One phase 2 study is recruiting. Everything else is observational: measuring the levels people already carry and correlating them with health.

So SS-31 is far further along, but further along here mostly means it has been properly tested and mostly did not work outside one rare disease. Any ordering of the two is community convention, not a finding.

Four different things that share a market and a set of forums, not a pharmacology.

Peptides are short chains of amino acids. They are water soluble and act mostly on receptors sitting on the outside surface of a cell, passing their message inwards. Digestion destroys them, which is why they are injected or sprayed rather than swallowed. The word describes a shape, not an effect: the category runs from insulin to compounds nobody has ever given to a person.

Anabolic steroids are small fat soluble molecules built on a cholesterol like skeleton. They slip straight through the cell membrane and act on a receptor inside the cell, changing which genes get read. In the UK they are class C controlled drugs.

SARMs, selective androgen receptor modulators, are not peptides at all. They are small non-steroidal molecules aimed at the same receptor as testosterone, designed to act more in muscle and bone than elsewhere. None has been approved as a medicine anywhere, which is why this library does not cover them.

Growth hormone is the hormone itself, a protein of 191 amino acids, and a licensed medicine for specific deficiencies. That is not the same as growth hormone peptides such as ipamorelin or CJC-1295, which nudge your own pituitary into releasing smaller, pulsed amounts of your own.

The takeaway worth keeping: peptides are not safer steroids, and they are not harmless just because they are different from steroids.

Mostly no, and the reason is chemistry rather than marketing.

The bond that holds a peptide together is exactly what your digestive enzymes exist to cut. Swallow one and your stomach and small intestine dismantle it like any other bit of protein, and whatever survives crosses the gut wall very poorly. For an ordinary peptide, oral absorption is typically under one per cent, and often effectively zero.

The exceptions prove the rule. Oral semaglutide is real, but it took serious engineering: an absorption enhancer built into the tablet, and strict fasting conditions around taking it, because even then very little gets through. That kind of product costs hundreds of millions to develop. A shop selling capsules of a peptide that's normally injected has not quietly solved the same problem.

Nasal sprays at least skip the gut, and a few licensed medicines genuinely work that way, desmopressin for instance. But absorption through the nose is still poor for most peptides, varies a lot between people and between doses, and depends on the formulation, not just the molecule. "Same peptide, just a spray" skips over the part that decides whether any of it arrives.

So the default assumption for an unlicensed oral, sublingual or nasal version of an injectable peptide is that most of it is destroyed or wasted before it reaches your blood. Injection isn't a preference or a habit. It's a consequence of the chemistry.

There's an enormous gap, which is exactly why we grade every compound in the directory.

Strongest: semaglutide and tirzepatide. These sit at the top by a distance. Tens of thousands of people in randomised placebo-controlled trials, replicated results, regulator scrutiny, and licences as medicines in the UK and US. Whatever else you think of them, the evidence is real.

Weakest among the popular ones: BPC-157, TB-500 and injected GHK-Cu.

• BPC-157: a large, positive animal literature and almost nothing in humans. A 2025 systematic review of the entire field found exactly one clinical study, a look back at twelve patients.
• TB-500: the peptide behind it, thymosin beta-4, genuinely reached late-stage human trials, but they never produced a clean win, and what's sold online is usually a short fragment of it, not the molecule that was actually tested.
• GHK-Cu: reasonable evidence as a skin cream ingredient is a different question from injecting it, and for injection there is no meaningful human data at all.

The pattern worth noticing: popularity online and strength of evidence have almost nothing to do with each other. Every compound on this site carries an evidence tier, from strong down through mixed and limited to preclinical, with the reasoning spelled out. Check any peptide's actual standing in the directory before someone else's certainty does your thinking for you.

Four different claims, four different evidence positions, and only one of them is anywhere near strong.

Libido. The exception. Bremelanotide, sold online as PT-141, is FDA approved for low sexual desire in premenopausal women on the back of two proper phase 3 trials. They met their targets, but the size of the effect deserves saying plainly: desire scores shifted a fraction of a point, and the number of satisfying sexual encounters did not rise significantly. Around four in ten people reported nausea. In men there is essentially no trustworthy controlled evidence at all, because the most cited male study now carries a formal Expression of Concern.

Sleep. DSIP was named for what its discoverers hoped it did. Fifty years on, no gene for it has been found and no receptor identified. The positive human sleep studies come mostly from the one group that championed it, and the independent double-blind study concluded the improvement was of little clinical significance.

Energy. MOTS-c is genuinely interesting biology, a peptide encoded by mitochondrial DNA, and it does impressive things in mice. No completed human trial of giving it to people has been published. Every claim about energy or fat loss is extrapolation from rodents.

Concentration. Semax and Selank are registered nasal medicines in Russia. Neither has been through a large independent placebo-controlled trial outside the former Soviet bloc, and there is no published controlled trial of Semax as a cognitive enhancer in healthy people.

Mostly yes, and the honest picture has three layers.

First, what happens by default. Body composition measurements inside the semaglutide and tirzepatide trials suggest roughly a quarter of the weight lost is lean tissue rather than fat. Before that alarms you: it's broadly the same proportion people lose through ordinary dieting. The peptide isn't eating your muscle; losing weight quickly does this whichever way you do it. Whether it matters over years, especially for older people, is a genuinely open question.

Second, what actually protects muscle. The boring, well-evidenced answer: resistance training and eating enough protein. Neither is a peptide, both have decades of evidence behind them, and they work alongside any weight loss method.

Third, the peptides marketed for this. Growth hormone secretagogues like ipamorelin are widely sold as muscle preservers to run alongside weight loss drugs. Here's the blunt bit: there is no published human trial showing any of them preserve muscle, in any context. Ipamorelin's only proper human trial was for a bowel condition, and it failed. "Raises growth hormone" is a hormone reading, not a body composition result.

So you can keep most of your muscle, but the tools that do it are the gym and your plate, not a second vial. If you're on a prescribed weight loss medicine and worried about muscle, that's exactly the conversation to have with the prescriber who knows your history.

People do this constantly, and the honest position is that nobody has tested it.

Take the stacks covered on this site: ten of the most popular combinations, and not one is backed by a controlled human trial of the combination itself. Only two have been tested at all, and both results cut against the marketing. A 2026 rat study gave BPC-157 and TB-500 separately and together for Achilles tendon healing, and the pair did no better than either one on its own.

Two problems come with stacking. The first is arithmetic: four compounds make six possible pairings, none of them studied, so nobody knows what they do to each other in the body. The second is that side effects add up even where benefits do not.

A third problem is yours, and it is the practical one. If you start three things at once and something changes, good or bad, you have no way of telling which one did it. Introducing one thing at a time, and giving it long enough to judge honestly, is the only way an individual gets usable information out of any of this. It is slower and far more informative.

If you want to know what the peptide community reports for a particular combination, ask me and I can walk you through it once I know a bit about you.

Cycling means running something for a stretch, then stopping for a stretch, on the theory that your body stops responding if you never give it a break.

The theory is real in places. Receptors can become less responsive when they are stimulated constantly. The clearest example in this library is hexarelin, a growth hormone releasing peptide: over a 16 week study the growth hormone response fell steadily, then returned to where it started once treatment stopped. The rest of that result is rarely quoted, though. IGF-1, body composition and bone density did not move at all across the whole study. So the pituitary did become less responsive, and nothing downstream had happened anyway.

Salmon calcitonin is another documented case, where the effect fades over days to weeks as receptors are pulled off the cell surface and antibodies build up against it.

Now the honest half. Most compounds people cycle have no desensitisation data of any kind, because nobody has given them to humans repeatedly and measured what happened. BPC-157 is the obvious one: after thirty years nobody has identified what it binds to, so there is no receptor to argue about.

The on and off lengths you see quoted are community convention. They were not derived from trials, because those trials do not exist. Somebody picked round numbers and everyone repeated them.

It depends completely on which peptide, and the honest answer splits into three groups.

Licensed medicines with real data. Semaglutide and tirzepatide have side effect profiles measured in tens of thousands of people. Gut effects dominate: nausea, vomiting, diarrhoea, constipation, reflux. Mostly mild to moderate, usually worst while the dose is being increased. In the SELECT trial roughly one in six people stopped semaglutide because of side effects, which is not a trivial number.

Research compounds. For most of what gets discussed online, including BPC-157, MOTS-c and DSIP, there is no human safety dataset at all. Not a reassuring one, none. That absence is itself the finding: nobody has looked, so nobody can tell you what an uncommon harm looks like or how often it turns up.

Problems with the product rather than the molecule. Injection site infection, and vials containing the wrong compound, the wrong amount, degradation products or bacterial contamination. This is documented in regulatory alerts and independent testing, and it has nothing to do with what the peptide is meant to do.

Stop and get seen the same day for: severe upper tummy pain going through to your back, sudden vision change especially in one eye, vomiting or diarrhoea lasting more than a day or two, a spreading hot red patch at an injection site, or any swelling or breathing reaction.

Tell the doctor exactly what you took and where it came from. They see this more often than you would think, and the thing that actually causes harm is leaving it out.

Nobody can hand you a list to go and tick off, and anyone selling you a fixed panel is guessing. What is worth understanding is the thinking behind it.

The principle is simple: you check the things a compound is known to move, plus the things that would quietly tell you something has gone wrong.

For the incretin medicines like semaglutide and tirzepatide, a good review looks at weight and waist, blood pressure and pulse, HbA1c if you have diabetes, and kidney bloods if there has been any vomiting or diarrhoea. That last one matters more than people expect. The kidney injury occasionally seen with these drugs is almost always dehydration from being unwell, not the drug attacking the kidney.

For anything working on the growth hormone axis, IGF-1 and blood glucose are the two that the pharmacology points at, because those are what such compounds actually move.

For most research peptides there is no monitoring plan anyone can honestly justify, because nobody knows what to look for. A set of baseline bloods before you start at least gives you something to compare against later, which beats nothing.

The real point is interpretation. Any of this needs someone who knows your history, your other medicines and your family history. A prescriber can read a result in context. A number on a private lab report, on its own, mostly just generates anxiety.

Some of this is clear cut, and some of it is a conversation.

Pregnancy and trying to conceive. The firmest one. GLP-1 medicines are not for use in pregnancy, and because semaglutide lingers in the body a long time, the product information says to stop well before a planned pregnancy and use reliable contraception meanwhile. A positive pregnancy test while on one is a same-day call to your prescriber. Bremelanotide is also not for use in pregnancy.

A personal or family history of medullary thyroid cancer or MEN2. A standard screening question before starting an incretin, and a formal contraindication in US labelling.

Anything already going on in the gut. Past pancreatitis, gallstones, gastroparesis, severe reflux, inflammatory bowel disease. None is an automatic no, but each shifts the balance.

People on insulin or sulfonylureas. Adding an incretin raises the risk of blood sugar dropping too low, so those doses usually get reviewed first.

Active cancer, for anything touching growth pathways. Growth hormone axis compounds and IGF-1 analogues are the concern.

One practical trap that gets missed: tirzepatide slows the stomach, which can affect how the contraceptive pill is absorbed around starting and around dose changes.

And the awkward category, which is large: anyone with a condition nobody has diagnosed yet. If you take regular medicines, or have a diagnosis of any kind, that is the conversation to have with a prescriber who has your history in front of them.

The answer differs by class, and the logic is worth following rather than taking on trust.

Growth pathway compounds. Growth hormone secretagogues and IGF-1 analogues raise IGF-1 deliberately. IGF-1 receptor signalling tells cells to grow and not to die, which is precisely its job. Observational studies consistently link higher circulating IGF-1 to modestly raised risk of prostate, breast and bowel cancer. That is an association, not proof of cause, and it is not the same as saying a peptide gives you cancer. It is why licensed products in this family, tesamorelin for instance, carry contraindications in active cancer. The concern is less about starting a cancer and more about feeding one nobody has found yet.

Incretins. Rodent studies of semaglutide showed thyroid C-cell tumours, which is why the labelling contraindicates use in people with a personal or family history of medullary thyroid cancer or MEN2. Whether that rodent finding carries over to humans is genuinely unresolved, and saying otherwise in either direction goes past the evidence.

Everything else. Nobody knows. Cancer risk is measured over decades in large populations, and no research peptide has been followed that way in anyone.

So: no peptide on this site is established as causing cancer in humans, and none has been shown not to. If you have had cancer, or there is a strong family history, that is a conversation with a prescriber who can see your records.

Yes, several do, and the documented examples are worth knowing about.

Heart rate. Retatrutide produced a dose-related rise in resting heart rate in its phase 2 trials, peaking a few months in and easing somewhat after. What that means for the heart over years is unknown, because the outcome trial that would answer it has not been published. Bremelanotide does something different: it briefly slows the pulse while nudging blood pressure up for a few hours after a dose, which is why its label rules it out in uncontrolled high blood pressure or known heart disease.

Blood sugar. Lowering it is the whole point of the incretins. Semaglutide and tirzepatide work in a glucose-dependent way, so on their own they rarely push it too low. Combined with insulin or a sulfonylurea they very much can, which is why those doses are usually reduced first, at the start rather than after the first bad episode.

Blood pressure. Weight loss on the incretins tends to bring it down, which is generally welcome, but it matters if you are already taking tablets for it.

Everything else. For research compounds none of this has been measured properly. Nobody reporting an effect is not the same as nobody having one.

If you take heart, blood pressure or diabetes medicines, this is exactly what a prescriber who knows your history should be checking before anything else.

Once water goes in, two clocks start running, and the shorter one sets the bin date.

Clock one is the peptide itself. In water it slowly degrades. How fast depends on the compound, and for unlicensed peptides nobody has actually measured it, so any confident shelf life you see online is a guess, not a fact. Keeping the vial in the fridge slows this clock right down.

Clock two is bacteria. The first time a needle goes through the rubber top, the sterile seal is broken. What happens next depends on your water. Bacteriostatic water contains a preservative that stops bacteria multiplying, so going back into the vial over several doses is defensible. The convention borrowed from clinical guidance on multi-dose vials is 28 days at the outside, and that assumes clean technique on every entry. It is a ceiling, not a target. Sterile water has no preservative, so guidance treats a vial mixed with it as a same-session thing: mix, use, bin the rest.

One caveat worth holding onto: 28 days is a bacteria rule, not a potency promise. Some peptides fade well inside that window, and neither fading nor contamination is visible. A clear solution proves nothing, which is why the date you write on the vial matters more than how it looks.

It depends entirely on whether the water has gone in yet.

Unmixed powder: yes. Freeze-dried powder has almost no free water in it, so there is nothing to form damaging ice. Freezing is a standard way to store dry peptide long term. Two practical points: let a cold vial warm to room temperature before opening it, because humid air condenses on cold glass and wets the powder, and avoid taking one vial in and out of the freezer repeatedly.

Mixed solution: no. Once the peptide is dissolved, freezing does real damage. Ice crystals physically tear at the molecules, the last unfrozen pocket becomes a harshly concentrated soup that makes peptide molecules clump together, and the acidity of the liquid can swing sharply. Every freeze and thaw repeats all of it. This is why licensed injectable peptide medicines carry a blanket do-not-freeze instruction, and why the NHS says frozen insulin goes in the bin.

The nasty part is that the damage is invisible. A solution that froze and thawed clear looks identical to one that never froze, and warming it back up undoes nothing. So if a mixed vial has been frozen, even by accident against the back wall of the fridge, treat it as gone. And store mixed vials on a middle shelf, away from the back wall, which is where most accidental freezing happens.

The whole point of bacteriostatic water is that it can be opened more than once. The small amount of benzyl alcohol in it stops bacteria multiplying, which is why it comes in multi-dose vials designed for repeated needle entries.

But stopping bacteria multiplying is not the same as killing everything. The preservative buys you margin against the few organisms that ride in on a needle. It does not sterilise the vial, and it will not rescue one that has been handled carelessly.

The working rule comes from clinical guidance on multi-dose vials: once the rubber top has been punctured for the first time, write the date on the vial and discard it within 28 days, and never use it past the printed expiry date, opened or not. That 28 days assumes clean technique, meaning a swabbed stopper allowed to dry and a fresh sterile needle for every single entry. Treat it as an outer limit rather than an entitlement.

And regardless of the calendar: if the water ever looks cloudy or has bits floating in it, or the stopper is damaged, bin it. Bacteriostatic water is the cheapest thing in the whole process, so replacing it early costs you almost nothing and removes a doubt you would otherwise carry into every vial you mix with it.

Yes, a bit, in two ways, and both are manageable.

The rubber top wears. Vial stoppers are designed to reseal, but only for a limited number of punctures. Going through the same spot over and over degrades the seal, and pushing a needle straight down can even core a tiny plug of rubber into the liquid. So vary where you puncture, and go in bevel up at an angle rather than stabbing vertically.

Every entry is a delivery route. The inside of the vial is sterile; the outer face of the rubber is not. Whatever sits on that surface gets carried straight through on the needle. That is why the routine matters:

1. Swab the stopper before every entry, not just the first, and let it dry fully. The drying is what disinfects.
2. Use a new sterile needle and syringe every time.
3. Never leave a needle parked in the stopper between doses. That holds the vial permanently open to the air, and it is a documented contamination route.

The preservative in bacteriostatic water gives you margin against small slips, but it suppresses growth rather than killing, so it is a back-up, not a substitute. If a vial will need many entries, mixing smaller amounts more often is the quieter fix: fewer punctures per vial, and less time with the seal broken.

Yes, and the single best trick is to travel with the powder, not the solution. Unmixed freeze-dried peptide tolerates days at room temperature, so for anything longer than a short trip the robust plan is to carry it dry and mix it when you arrive.

If you must travel with a mixed vial:

• Hand luggage, never the hold. The hold can drop below freezing, which wrecks a solution, and bags go missing.
• Insulated bag with a gel pack, but never let the pack touch the glass, because direct contact can freeze the vial. Wrap it in a cloth. Evaporative cooling wallets hold cool room temperature, not fridge temperature.
• Never leave vials in a parked car. Interiors easily pass fifty degrees in the sun.
• The discard date runs on calendar days whether you are travelling or not. Time in a cool bag still counts.

The awkward bit, said plainly: airport rules allow needles and medical liquids over 100ml in hand luggage, but they expect supporting paperwork, and for an unprescribed compound you will not have a prescription or a doctor's letter. Original labelled packaging kept together in one clear bag is the best evidence you can offer. Expect questions and answer them calmly. And some countries restrict compounds that are unremarkable in the UK, so check the destination's import rules before you fly, not at the check-in desk.

Trust it the way you'd trust a photo of someone else's dinner: it might be perfectly real, but it isn't yours.

Three checks. First, the batch number on the certificate must match the one on your vial. Most worthless COAs aren't clever forgeries, they're genuine reports from one good batch reused for every batch since. No batch number means no link to what you're holding.

Second, a real report comes from a real lab: a name, an address, a report number you could email them to confirm. A smooth graph on a blank page with none of that is a drawing of a test, not a test.

Third, know what a COA never covers. It measures identity and purity, which are chemistry questions. It says nothing about sterility (whether anything is growing in it) or endotoxin, the fever-causing debris left behind by bacteria, which is invisible and survives filtering. If those aren't on the page with a method and a number, they weren't tested.

And even a perfect certificate describes one sample from one batch, not your vial. The only result that ties to your actual material is a vial from your own order, sent to an independent lab. That costs money and destroys the vial, which is why almost nobody does it, and why batch-matched, independently verified testing is the standard worth holding suppliers to.

A properly mixed peptide should end up completely clear, with nothing floating in it. A little haze while the powder dissolves is normal, and it should clear within a minute or two of gentle swirling. If it still looks milky after fifteen or twenty minutes standing, that isn't slow dissolving.

Persistent cloudiness means aggregation: the peptide molecules have unfolded and stuck to each other. Threads, strands or a gel that barely moves when you tilt the vial are the same problem further along, the chains tangled into fibres that trap the liquid. At that point you can't know how much intact peptide is left, and clumped peptide is exactly what the immune system reacts to most readily. Bin it, and don't try to rescue it by warming, filtering or adding more water. None of those undo the chemistry.

The usual causes are handling rather than fraud: shaking instead of swirling, water squirted hard onto the powder instead of run down the glass, heat, or freezing and thawing. One honest exception: very cold water can throw a mist of tiny bubbles as it warms, which looks cloudy but rises and clears if you leave the vial standing.

One more thing worth noticing. If one vial from a kit goes cloudy or gels while its siblings, mixed the same way, behave fine, that points at inconsistent manufacture rather than your technique. Treat it as a red flag about the product.

Here's the honest checklist, roughly in order of likelihood.

1. It may not contain what the label promises. Unverified vials are the single biggest suspect. A vial can be underdosed, degraded, or a different compound entirely, and nothing about how it looks or dissolves would tell you. Most people never test what they buy.

2. Handling may have damaged it. Shaking, heat, freezing and thawing, and weeks sitting mixed at room temperature all break peptides down. A ruined peptide looks exactly like a working one.

3. Your expectations may not fit what it does. Even the best-evidenced compounds work gradually and undramatically. If you're expecting to feel something in week one, most peptides were never going to deliver that, real or not.

4. It may not work in anyone. This is the uncomfortable one. For many popular peptides there is no human trial showing they do anything at all. The whole reputation rests on animal studies and word of mouth. If a compound has never been shown to work in people, "it isn't working for me" might simply be the accurate result.

Notice what's missing from that list: needing more. That's usually the first explanation people reach for and the least justified, because it assumes points one to four are all ruled out. They almost never are.

Every compound's page here shows exactly what human evidence exists, so you can check which situation you're actually in.

It depends entirely on which peptide, and the difference matters.

Licensed metabolic drugs (semaglutide, tirzepatide): many people notice their appetite changing within the first couple of weeks. Weight loss builds far more slowly, for two reasons. These weekly drugs take several weeks to build up to a steady level in the blood, and prescribers step the dose up gradually over months, so early doses are deliberately below the full amount. The trial results you see quoted, 15 or 20% of body weight, were measured after well over a year. Expecting that in a couple of months is a misread, not a failure.

Research compounds (BPC-157, ipamorelin and the rest): nobody knows, and that isn't a dodge. No proper human trials have measured these outcomes, so no honest timeline exists. Everything quoted online is anecdote.

When absence of effect means something: with a licensed medicine, trials show most people see some measurable change within the first few months. Nothing at all is real information, worth raising with your prescriber, who can adjust or switch.

With a grey-market vial, no effect tells you almost nothing, because you can't separate "this compound doesn't work" from "this vial didn't contain what the label claimed". Underdosed and mislabelled vials are documented often enough that this is a live possibility, which is why a batch-matched certificate of analysis and independent testing matter before anything else does.

It depends entirely on which peptide and what you're doing with it, so here's the shape of it.

Approved peptide medicines (insulin, the licensed weight-loss injections) are prescription-only in both the UK and US: lawful to possess with a prescription, unlawful to supply without one. A doctor can also prescribe these off-label, meaning outside the licensed use, which is a legitimate and common practice.

Unapproved peptides, the ones sold in vials online, sit in murkier territory. Selling an unlicensed product for human use is a medicines offence, which is exactly why vendors label everything "research use only". That label is a liability shield, not a quality standard: it promises nothing about sterility, manufacture, or whether the vial contains what it says. Personal possession is generally not itself criminalised for most of these compounds, but imports can be intercepted, and anything separately controlled under other laws carries its own position.

Two more things worth knowing. "Medically approved" means a regulator has examined the manufacturing, the human trials and the harms; almost none of these compounds have that, anywhere. And many are banned in competitive sport at all times, not just on competition day.

This is genuinely unsettled law, and I'm not a lawyer. If the legal question matters for your situation, ask one.

Honest answer: it varies so much that any number I gave you would be misleading. But the shape of the costs is worth understanding.

The clinic route. You pay for consultations, prescribing, a licensed medicine and follow-up. It costs more, and what the extra money buys is verification: a product checked at every step of manufacture, and a prescriber who knows your history watching for problems.

The grey market route. The vial is cheaper, but the vial isn't the whole cost. To have real confidence in what you're injecting, you'd want a certificate of analysis (a lab report on your exact batch) and ideally independent testing of your own vial, which you pay for separately. Then add bacteriostatic water, syringes, needles, swabs and sharps disposal. Price all of that honestly and the gap narrows.

And here's why cheap can be expensive: a bargain vial with no batch-matched paperwork might be underdosed, impure, or contain nothing at all. If it does nothing, you've paid full price for salt water. If it's contaminated, the cost stops being financial.

BioRx doesn't sell anything yet and doesn't vet suppliers; we're testing suppliers for full traceability first, and there's a waitlist. What I can do now is teach you to judge the paperwork, so ask me about reading a certificate of analysis any time.

For most peptides the honest pattern is this: the benefit fades when you stop, because the compound was doing the work while it was present, not fixing anything permanently.

The clearest data comes from the licensed weight-loss injections. In the semaglutide trial extension, people who stopped regained roughly two-thirds of the weight they'd lost within a year, and the improvements in blood pressure and blood sugar reversed alongside it. The drug quiets appetite while it's in your system; it doesn't reset anything underneath. That's why it's licensed as a long-term treatment, not a short course. The same shape shows up with other licensed peptides: the fat lost on tesamorelin returns after stopping, and bone built with teriparatide starts declining once it's withdrawn unless another medicine follows it.

For the research compounds, nobody knows. Stopping has never been formally studied for them, because almost nothing about them has. So there's no evidence of rebound problems, but no evidence of anything else either.

The useful mental model: benefits are not banked. Whatever a peptide was doing, expect your body to drift back toward its own baseline over weeks to months once it's gone.

One caution: if you're on a prescribed medicine, especially anything affecting hormones, blood sugar or blood pressure, don't stop abruptly on your own. Talk it through first with the prescriber who knows your history.

*BioRx is an independent, non-commercial education library. We sell nothing and have no

commercial relationship with any manufacturer or vendor. Corrections and sourcing queries:

see the about page.*